Drug Trial Radar · NCT05349968
Pharmacokinetics and Efficacy of Multiple Dosing of Lipovirtide for Injection in HIV-infected Patients
Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Jun 10, 2022
Primary completion
Jun 7, 2023
Study completion Sep 7, 2023
Sponsor
- Lead sponsor
- Shanxi Kangbao Biological Product Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Institute of Pathogen Biology, Beijing, China
- First posted
- Apr 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objectives 1.Evaluation of safety and tolerability after repeated administration of injectable Lipivirtide in HIV-infected patients not receiving antiretroviral therapy Secondary Objectives 1. Evaluation of the pharmacokinetic properties of injectable Lipovirtide after multiple administrations in HIV-infected patients not receiving antiretroviral therapy, to obtain pharmacokinetic parameters. 2. Evaluation of the efficacy of injectable Lipovirtide for HIV in HIV-infected patients not receiving antiretroviral therapy. 3. Evaluation of the immunogenicity of lipovirtide for injection.
Conditions
- HIV Infections
Interventions
Lipovirtide for injectionDrug
Multiple dosing of Lipovirtide
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes from baseline in respiration rate of Vital Signs.Time frame: Within 50 days after the first administration.
- Changes from baseline in Blood lactate of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in Pregnancy test of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in Drug resistance test of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in Immunogenic blood collection of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in blood pressure of Vital Signs.Time frame: Within 50 days after the first administration.
- Changes from baseline in body temperature of Vital Signs.Time frame: Within 50 days after the first administration.
- Changes from baseline in red blood cell count of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in white blood cell count of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in neutrophil count of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in lymphocyte count of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in platelet count of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in hemoglobin of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in PT of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in INR of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in APTT of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in total bilirubin of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in direct bilirubin of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in ALT of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in AST of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in total protein of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in albumin of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in total bile acid of Laboratory ExaminationTime frame: Within 50 days after the first administration.
- Changes from baseline in urea of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in creatinine of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in uric acid of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in glucose of Laboratory ExaminationTime frame: Within 50 days after the first administration.
- Changes from baseline in potassium of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in sodium of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in chlorine of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in urine specific gravity of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in urine pH of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in urine glucose of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in urine protein of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in urine ketone body of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in urine white blood cell of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in urine bilirubin of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in urine occult blood of Laboratory Examination.Time frame: Within 50 days after the first administration.
- Changes from baseline in Electrocardiogram.Time frame: Within 50 days after the first administration.
- Changes from baseline in CK of Laboratory ExaminationTime frame: Within 50 days after the first administration.
- Changes from baseline in CK-MB of Laboratory ExaminationTime frame: Within 50 days after the first administration.
- Changes from baseline in LDH of Laboratory ExaminationTime frame: Within 50 days after the first administration.
- Changes from baseline in ALP of Laboratory ExaminationTime frame: Within 50 days after the first administration.
- Changes from baseline in Triglyceride of Laboratory ExaminationTime frame: Within 50 days after the first administration.
- Changes from baseline in CHOL of Laboratory ExaminationTime frame: Within 50 days after the first administration.
- Changes from baseline in TP of Laboratory ExaminationTime frame: Within 50 days after the first administration.
- Changes from baseline in ALB of Laboratory ExaminationTime frame: Within 50 days after the first administration.
- Changes from baseline in UA of Laboratory ExaminationTime frame: Within 50 days after the first administration.
- Changes from baseline in GLU of Laboratory ExaminationTime frame: Within 50 days after the first administration.
- Changes from baseline in AMY of Laboratory ExaminationTime frame: Within 50 days after the first administration.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing You'an Hospital, Beijing Medical University
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.